Foundation for Vision Research

Grand Rapids, Michigan 49546

4 studies enrolling now · 22 studies all time

What they study most

Age-Related Macular Degeneration, DME, Diabetic Macular Edema, Diabetic Macular Edema (DME), Geographic Atrophy, Macular Degeneration, Macular Edema, Macular Telangiectasia Type 2, Macular Telangiectasia Type 2 (MacTel), Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD), Non-proliferative Diabetic Retinopathy

Studies at this site

• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME — Recruiting now
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants — Recruiting now
• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Recruiting now
• Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — Recruiting now
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) — Running, not enrolling
• Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration — Running, not enrolling
• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Study to Determine the Safety and Efficacy of NT-501 With MHFM — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) — Stopped early
• A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) — Stopped early
• Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. — Stopped early
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) — Completed
• A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration — Completed
• A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early